Identifies cytochrome P450-mediated metabolic drug interactions.
Add Drugs to Regimen
Pharmacogenomics / Metabolizer StatusNot set▾
CYP2D6 phenotype
CYP2C19 phenotype
PM = poor metabolizer · IM = intermediate · NM = normal · UM = ultrarapid. When set, analysis will include CPIC-guideline phenotype recommendations for relevant drugs. Re-run analysis after changing status.
History0 saved▾
No saved analyses yet. Run an analysis to save it here.
⬡
Add two or more drugs to begin analysis
Educational reference only. Inhibitor and inducer classifications are sourced from the FDA's Examples of Drugs that Interact with CYP Enzymes and Transporter Systems (updated June 2025). Substrate profiles marked with a dashed border (~) were supplemented from standard pharmacology literature (Goodman & Gilman, Flockhart table, drug labeling) where the FDA table lacks substrate classification — these entries identify the metabolic pathway but do not carry FDA-defined AUC fold-change classifications. Transporter-mediated interactions (P-gp, OATP, OAT, etc.) are not included. This tool does not account for pharmacodynamic interactions, dose-dependent effects, genetic polymorphisms, or prodrug activation. Do not use for clinical decision-making — consult Lexicomp, Micromedex, or a clinical pharmacist.
⌕
Show only:
Drug ↑
Class
Substrate of
Inhibits
Induces
PGx
Educational reference only. Inhibitor and inducer classifications are sourced from the FDA's Examples of Drugs that Interact with CYP Enzymes and Transporter Systems (updated June 2025). Substrate profiles marked ~ are literature-sourced and do not carry FDA-defined AUC fold-change classifications. Do not use for clinical decision-making.